Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; Oct2023, Vol. 11 Issue 10, p894-904, 11p
- Subject
SEPTIC shock INTENSIVE care units PATIENT selection SHOCK therapy - Language
- ISSN
- 22132600